全文获取类型
收费全文 | 33755篇 |
免费 | 2099篇 |
国内免费 | 267篇 |
专业分类
耳鼻咽喉 | 445篇 |
儿科学 | 608篇 |
妇产科学 | 504篇 |
基础医学 | 4146篇 |
口腔科学 | 1561篇 |
临床医学 | 2748篇 |
内科学 | 9066篇 |
皮肤病学 | 445篇 |
神经病学 | 3386篇 |
特种医学 | 1326篇 |
外科学 | 5390篇 |
综合类 | 93篇 |
一般理论 | 6篇 |
预防医学 | 1416篇 |
眼科学 | 554篇 |
药学 | 1845篇 |
中国医学 | 72篇 |
肿瘤学 | 2510篇 |
出版年
2024年 | 32篇 |
2023年 | 362篇 |
2022年 | 676篇 |
2021年 | 1270篇 |
2020年 | 753篇 |
2019年 | 1033篇 |
2018年 | 1219篇 |
2017年 | 964篇 |
2016年 | 1076篇 |
2015年 | 1142篇 |
2014年 | 1481篇 |
2013年 | 1799篇 |
2012年 | 2817篇 |
2011年 | 2704篇 |
2010年 | 1523篇 |
2009年 | 1394篇 |
2008年 | 2177篇 |
2007年 | 2284篇 |
2006年 | 2060篇 |
2005年 | 1868篇 |
2004年 | 1670篇 |
2003年 | 1523篇 |
2002年 | 1323篇 |
2001年 | 284篇 |
2000年 | 253篇 |
1999年 | 268篇 |
1998年 | 249篇 |
1997年 | 205篇 |
1996年 | 160篇 |
1995年 | 143篇 |
1994年 | 128篇 |
1993年 | 108篇 |
1992年 | 126篇 |
1991年 | 101篇 |
1990年 | 92篇 |
1989年 | 65篇 |
1988年 | 98篇 |
1987年 | 64篇 |
1986年 | 50篇 |
1985年 | 68篇 |
1984年 | 56篇 |
1983年 | 43篇 |
1982年 | 50篇 |
1981年 | 30篇 |
1980年 | 26篇 |
1979年 | 41篇 |
1978年 | 30篇 |
1977年 | 22篇 |
1973年 | 32篇 |
1972年 | 26篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
991.
992.
Collins P Baudo F Knoebl P Lévesque H Nemes L Pellegrini F Marco P Tengborn L Huth-Kühne A;EACH registry collaborators 《Blood》2012,120(1):47-55
Acquired hemophilia A (AHA) is an autoimmune disease caused by an autoantibody to factor VIII. Patients are at risk of severe and fatal hemorrhage until the inhibitor is eradicated, and guidelines recommend immunosuppression as soon as the diagnosis has been made. The optimal immunosuppressive regimen is unclear; therefore, data from 331 patients entered into the prospective EACH2 registry were analyzed. Steroids combined with cyclophosphamide resulted in more stable complete remission (70%), defined as inhibitor undetectable, factor VIII more than 70 IU/dL and immunosuppression stopped, than steroids alone (48%) or rituximab-based regimens (59%). Propensity score-matched analysis controlling for age, sex, factor VIII level, inhibitor titer, and underlying etiology confirmed that stable remission was more likely with steroids and cyclophosphamide than steroids alone (odds ratio = 3.25; 95% CI, 1.51-6.96; P < .003). The median time to complete remission was approximately 5 weeks for steroids with or without cyclophosphamide; rituximab-based regimens required approximately twice as long. Immunoglobulin administration did not improve outcome. Second-line therapy was successful in approximately 60% of cases that failed first-line therapy. Outcome was not affected by the choice of first-line therapy. The likelihood of achieving stable remission was not affected by underlying etiology but was influenced by the presenting inhibitor titer and FVIII level. 相似文献
993.
Littera R Orrù N Caocci G Sanna M Mulargia M Piras E Vacca A Giardini C Orofino MG Visani G Bertaina A Giorgiani G Locatelli F Carcassi C La Nasa G 《British journal of haematology》2012,156(1):118-128
In a study conducted on 114 patients undergoing unrelated donor haematopoietic stem cell transplantation (HSCT) for thalassaemia, we observed that the lack of activating killer immunoglobulin-like receptors (KIRs) on donor natural killer (NK) cells significantly increased the risk of graft-versus-host disease (GvHD) [hazard risk (HR) 4.2, 95% confidence interval (CI) 1.7-10.1, P = 0.002] and transplantation-related mortality (HR 4.7, 95% CI 1.6-14.2, P = 0.01). The risk of GvHD furthermore increased when recipients heterozygous for HLA-C KIR ligand groups (C1/C2) were transplanted from donors completely lacking activating KIRs (HR 6.1, 95% CI 1.9-19.2, P = 0.002). We also found that the risk of rejection was highest when the recipient was homozygous for the C2 HLA-KIR ligand group and the donor carried two or more activating KIRs (HR 6.8, 95% CI 1.9-24.4, P = 0.005). By interpolating the number of donor activating KIRs with recipient HLA-C KIR ligands, we created an algorithm capable of stratifying patients according to the immunogenetic risk of complications following unrelated HSCT. In clinical practice, this predictive tool could serve as an important supplement to clinical judgement and decision-making. 相似文献
994.
Ciavarella S Grisendi G Dominici M Tucci M Brunetti O Dammacco F Silvestris F 《British journal of haematology》2012,157(5):586-598
Recently, genetically modified mesenchymal stem cells (MSCs) have been exploited to deliver anti-cancer bio-drugs directly within the tumour mass. Here, we explored whether adipose-derived MSCs (AD-MSCs), engineered to express the pro-apoptotic ligand TRAIL (also known as TNFSF10), kill multiple myeloma (MM) cells and migrate towards MM cells in vitro. Different MM cell lines were assessed for their sensitivity to recombinant human (rh) TRAIL alone and in combination with the proteasome inhibitor bortezomib, which was shown to enhance the effect of rhTRAIL. TRAIL(+) -AD-MSCs were co-cultured with bortezomib-pretreated MM cells and their killing activity was evaluated in presence or absence of caspase inhibition. AD-MSC migration towards media conditioned by both myeloma cells and myeloma bone fragments was also investigated. Despite moderate MM cell sensitivity to rhTRAIL, TRAIL(+) -AD-MSCs in combination with bortezomib significantly induced myeloma cell death. This effect was associated with caspase-8 activation and abrogated by capsase inhibition. On the other hand, co-culture experiments were performed to evaluate whether unmodified AD-MSCs affect myeloma cell growth in vitro. AD-MSCs appeared ineffective on myeloma cell growth and showed migratory capacity towards MM cells in vitro. These data emphasize the anti-myeloma activity of TRAIL-engineered AD-MSCs and provide support for a future model of a cell-based approach against MM. 相似文献
995.
996.
997.
998.
999.
1000.
Fetal growth restriction and preeclampsia are both conditions of placental etiology and associated to increased risk for the long-term development of cardiovascular disease in the mother. At presentation, preeclampsia is associated with maternal global diastolic dysfunction, which is determined, at least in part, by increased afterload and myocardial stiffness. The aim of this study is to test the hypothesis that women with normotensive fetal growth-restricted pregnancies also exhibit global diastolic dysfunction. This was a prospective case-control study conducted over a 3-year period involving 29 preterm fetal growth-restricted pregnancies, 25 preeclamptic with fetal growth restriction pregnancies, and 58 matched control pregnancies. Women were assessed by conventional echocardiography and tissue Doppler imaging at diagnosis of the complication and followed-up at 12 weeks postpartum. Fetal growth-restricted pregnancies are characterized by a lower cardiac index and higher total vascular resistance index than expected for gestation. Compared with controls, fetal growth-restricted pregnancy was associated with significantly increased prevalence (P<0.001) of asymptomatic left ventricular diastolic dysfunction (28% versus 4%) and widespread impaired myocardial relaxation (59% versus 21%). Unlike preeclampsia, cardiac geometry and intrinsic myocardial contractility were preserved in fetal growth-restricted pregnancy. Fetal growth-restricted pregnancies are characterized by a low output, high resistance circulatory state, as well as a higher prevalence of asymptomatic global diastolic dysfunction and poor cardiac reserve. These findings may explain the increased long-term cardiovascular risk in these women who have had fetal growth-restricted pregnancies. Further studies are needed to clarify the postnatal natural history of cardiac dysfunction in these women. 相似文献